Biofrontera Inc. (NASDAQ:BFRI) Short Interest Up 69.5% in March

Biofrontera Inc. (NASDAQ:BFRI) was the target of a significant increase in short interest in March. As of March 31st, there was short interest totaling 295,934 shares, an increase of 69.5% from the March 15th total of 174,589 shares. Currently, 2.7% of the company’s stock are short sold. Based on an average trading volume of 124,454 shares, the short-interest ratio is presently 2.4 days.

Biofrontera Price Performance

Shares of NASDAQ BFRI opened at $1.03 on Monday. The stock’s 50-day moving average is $0.87 and its two-hundred day moving average is $0.89. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.52 and a quick ratio of 1.40. The company has a market cap of $12.00 million, a price-to-earnings ratio of -1.00 and a beta of 0.63. Biofrontera has a 1-year low of $0.54 and a 1-year high of $1.19.

Biofrontera (NASDAQ:BFRI) last posted its quarterly earnings results on Thursday, March 19th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.29 by $0.21. The company had revenue of $17.10 million during the quarter, compared to analysts’ expectations of $16.15 million. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%. Analysts forecast that Biofrontera will post -3.01 EPS for the current fiscal year.

Institutional Trading of Biofrontera

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC grew its position in shares of Biofrontera by 54.2% in the 4th quarter. Geode Capital Management LLC now owns 65,677 shares of the company’s stock valued at $37,000 after buying an additional 23,074 shares during the last quarter. Rosalind Advisors Inc. grew its holdings in shares of Biofrontera by 16.8% during the third quarter. Rosalind Advisors Inc. now owns 1,140,764 shares of the company’s stock worth $1,124,000 after purchasing an additional 164,316 shares during the last quarter. Finally, AIGH Capital Management LLC increased its position in shares of Biofrontera by 7.3% during the third quarter. AIGH Capital Management LLC now owns 1,046,050 shares of the company’s stock worth $1,030,000 after purchasing an additional 71,525 shares in the last quarter. Institutional investors and hedge funds own 10.08% of the company’s stock.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.